Cargando…

Neoadjuvant PD-1 blockade plus chemotherapy versus chemotherapy alone in locally advanced stage II-III gastric cancer: A single-centre retrospective study

BACKGROUND: PD-1 blockade has been shown to have promising efficacy and acceptable safety profiles in advanced and metastatic gastric cancer; however, the efficacy and safety of neoadjuvant PD-1 blockade-based immunotherapy plus chemotherapy in locally advanced gastric cancer (LAGC) remain uncertain...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Xuchen, Zhang, Chuantao, Hou, Helei, Zhang, Yuming, Jiang, Peng, Zhou, Hai, Wang, Lele, Zhou, Na, Zhang, Xiaochun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10034143/ https://www.ncbi.nlm.nih.gov/pubmed/36934638 http://dx.doi.org/10.1016/j.tranon.2023.101657

Ejemplares similares

Neoadjuvant PD-1 blockade combined with chemotherapy is not superior to neoadjuvant chemotherapy alone in resectable locally advanced esophageal carcinoma
por: Cheng, Daoan, et al.
Publicado: (2023)

Neoadjuvant PD-1 blockade plus chemotherapy induces a high pathological complete response rate and anti-tumor immune subsets in clinical stage III gastric cancer
por: Tang, Xiaohuan, et al.
Publicado: (2022)

Chemotherapy Alters the Phylogenetic Molecular Ecological Networks of Intestinal Microbial Communities
por: Cong, Jing, et al.
Publicado: (2019)

Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab compared with chemotherapy alone and chemoradiotherapy for locally advanced esophageal squamous cell cancer
por: Zhang, Baihua, et al.
Publicado: (2023)

Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II–III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial
por: Zhu, Xinsheng, et al.
Publicado: (2022)

Response to apatinib in chemotherapy-failed advanced spindle cell breast carcinoma
por: Zhou, Na, et al.
Publicado: (2016)

Neoadjuvant programmed death-1 blockade plus chemotherapy in locally advanced esophageal squamous cell carcinoma
por: Yang, Guozhen, et al.
Publicado: (2021)

Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial: A randomized clinical trial of neoadjuvant therapy for ESCC
por: Li, Yong, et al.
Publicado: (2023)

PD-1 blockade combined with gemcitabine plus nab-paclitaxel is superior to chemotherapy alone in the management of unresectable stage III/IV pancreatic cancer: a retrospective real-world study
por: Cheng, Daoan, et al.
Publicado: (2023)

Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis
por: Guo, Xiaodi, et al.
Publicado: (2020)

Distribution of residual tumors in esophageal squamous cell carcinoma after neoadjuvant PD-1 blockade combined with chemotherapy
por: Jiang, Dongxian, et al.
Publicado: (2023)

Genomic and Immune Profiling of a Patient With Triple-Negative Breast Cancer That Progressed During Neoadjuvant Chemotherapy Plus PD-L1 Blockade
por: Casadevall, David, et al.
Publicado: (2019)

Comparison of neoadjuvant immunotherapy plus chemotherapy versus chemotherapy alone for patients with locally advanced esophageal squamous cell carcinoma: A propensity score matching
por: Jing, Shao-Wu, et al.
Publicado: (2022)

Neoadjuvant PD‐1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung
por: Feng, Yuan, et al.
Publicado: (2021)

Cost-effectiveness analysis of toripalimab plus chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer in China
por: Zhang, Mengdie, et al.
Publicado: (2023)

Successful outcome of neoadjuvant PD-1 blockade, VEGFR-2 inhibitor plus chemotherapy for potentially unresectable esophagogastric junctional squamous cell carcinoma: a case report
por: Chen, Kai-Bo, et al.
Publicado: (2022)

Comparison of perioperative outcomes among non-small cell lung cancer patients with neoadjuvant immune checkpoint inhibitor plus chemotherapy, EGFR-TKI, and chemotherapy alone: a real-world evidence study
por: Zhao, Deping, et al.
Publicado: (2022)

Identification of surrogate endpoints in patients with locoregionally advanced nasopharyngeal carcinoma receiving neoadjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone
por: Chen, Yu-Pei, et al.
Publicado: (2015)

PD-1/PD-L1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in first-line treatment for non-squamous non-small-cell lung cancer
por: Yu, Hui, et al.
Publicado: (2021)

Safety and efficacy of tislelizumab plus chemotherapy versus chemotherapy alone as neoadjuvant treatment for patients with locally advanced gastric cancer: real-world experience with a consecutive patient cohort
por: Jiang, Qi, et al.
Publicado: (2023)

Chemotherapy Plus Radiotherapy Versus Chemotherapy Alone for Patients With Peripheral T-Cell Lymphoma, Not Otherwise Specified
por: Chen, Zegeng, et al.
Publicado: (2021)

Neoadjuvant Bevacizumab plus Chemotherapy versus Chemotherapy Alone to Treat Non-Metastatic Breast Cancer: A Meta-Analysis of Randomised Controlled Trials
por: Cao, Li, et al.
Publicado: (2015)

Neoadjuvant apatinib plus tegafur/gimeracil/oteracil potassium (S‑1)/oxaliplatin chemotherapy vs. chemotherapy alone in patients with locally advanced gastric carcinoma
por: Wang, Zhenfeng, et al.
Publicado: (2022)

PD-1 blockade potentiates neoadjuvant chemotherapy in NSCLC via increasing CD127(+) and KLRG1(+) CD8 T cells
por: Hui, Zhenzhen, et al.
Publicado: (2023)

Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma
por: Chen, Yongshun, et al.
Publicado: (2018)

EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers
por: Smyth, Elizabeth C, et al.
Publicado: (2021)

Neoadjuvant PD-1 Inhibitor Plus Apatinib and Chemotherapy Versus Apatinib Plus Chemotherapy in Treating Patients With Locally Advanced Gastric Cancer: A Prospective, Cohort Study
por: Wang, Chunjing, et al.
Publicado: (2023)

Efficacy and safety of PD‐1/PD‐L1 inhibitor plus chemotherapy versus chemotherapy alone as first‐line treatment for extensive‐stage small cell lung cancer: A systematic review and meta‐analysis
por: Zhang, Shuang, et al.
Publicado: (2020)

Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer
por: Li, Song, et al.
Publicado: (2023)

Neoadjuvant immune checkpoint inhibitor plus chemotherapy in rare tracheal tumors
por: Jiang, Ben‐Yuan, et al.
Publicado: (2021)

Neoadjuvant Immuno-Chemotherapy: A New Perspective for Stage III NSCLC?
por: Yao, Yuanshan, et al.
Publicado: (2022)

Addendum: Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma
por: Chen, Yongshun, et al.
Publicado: (2022)

Local radiotherapy alone following neoadjuvant chemotherapy and surgery in combined clinical stage II and III breast cancer
por: White, Rohen, et al.
Publicado: (2016)

The efficacy and safety of apatinib for refractory malignancies: a review and meta-analysis
por: Sun, Dantong, et al.
Publicado: (2018)

A phase II, single-centre trial of neoadjuvant toripalimab plus chemotherapy in locally advanced esophageal squamous cell carcinoma
por: Xing, Wenqun, et al.
Publicado: (2020)

A Comparison of Intravenous plus Intraperitoneal Chemotherapy with Intravenous Chemotherapy Alone for the Treatment of Gastric Cancer: A Meta-Analysis
por: Yang, Sheng, et al.
Publicado: (2015)

Randomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study)
por: Hasegawa, Yoshie, et al.
Publicado: (2015)

A phase III study on neoadjuvant chemotherapy versus neoadjuvant toripalimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: Henan Cancer Hospital Thoracic Oncology Group 1909 (HCHTOG1909)
por: Zheng, Yan, et al.
Publicado: (2021)

Neoadjuvant chemotherapy (NCT) plus targeted agents versus NCT alone in colorectal liver metastases patients: A systematic review and meta-analysis
por: Cui, Chun-Hui, et al.
Publicado: (2015)

Comparison of Surgery Plus Chemotherapy and Palliative Chemotherapy Alone for Advanced Gastric Cancer with Krukenberg Tumor
por: Cho, Jang Ho, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_rf6clbg6cl4s3v623c034g2i2h